Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.

[1]  E. DeLong,et al.  Secondary Prevention After Coronary Artery Bypass Graft Surgery: Findings of a National Randomized Controlled Trial and Sustained Society-Led Incorporation Into Practice , 2011, Circulation.

[2]  Yujun Wu,et al.  Fast FSR Variable Selection with Applications to Clinical Trials , 2009, Biometrics.

[3]  L. Chiariello,et al.  Long-term outcome of coronary artery bypass grafting in patients with left ventricular dysfunction. , 2009, The Annals of thoracic surgery.

[4]  Christopher M O'Connor,et al.  Coronary bypass surgery with or without surgical ventricular reconstruction. , 2009, The New England journal of medicine.

[5]  Patrick Royston,et al.  How should variable selection be performed with multiply imputed data? , 2008, Statistics in medicine.

[6]  M. Conte.  Molecular engineering of vein bypass grafts. , 2007, Journal of vascular surgery.

[7]  Rowena J Dolor,et al.  Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. , 2007, Journal of the American College of Cardiology.

[8]  R. Califf,et al.  Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. , 2007, The Annals of thoracic surgery.

[9]  Xinjiang Cai,et al.  New therapeutic possibilities for vein graft disease in the post-edifoligide era. , 2006, Future cardiology.

[10]  V. Falk,et al.  Endoscopic Vascular Harvest in Coronary Artery Bypass Grafting Surgery: A Consensus Statement of the International Society of Minimally Invasive Cardiothoracic Surgery (ISMICS) 2005 , 2005, Innovations.

[11]  Prevent Iv Investigators.  Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. , 2005 .

[12]  L. Liao,et al.  Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. , 2005, The American journal of cardiology.

[13]  Robert M Califf,et al.  The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics. , 2005, American heart journal.

[14]  A. de Bruin,et al.  Cloning and Characterization of Mouse E2F8, a Novel Mammalian E2F Family Member Capable of Blocking Cellular Proliferation* , 2005, Journal of Biological Chemistry.

[15]  P. Widimsky,et al.  One-Year Coronary Bypass Graft Patency: A Randomized Comparison Between Off-Pump and On-Pump Surgery Angiographic Results of the PRAGUE-4 Trial , 2004, Circulation.

[16]  J. Bonventre,et al.  TRIP-Br Links E2F to Novel Functions in the Regulation of Cyclin E Expression During Cell Cycle Progression and in the Maintenance of Genomic Stability , 2004, Cell cycle.

[17]  K. Malmberg,et al.  Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. , 2004, Journal of the American College of Cardiology.

[18]  Constance K Haan,et al.  Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women , 2004, Circulation.

[19]  V. Vaccarino,et al.  Long-term benefits of coronary bypass surgery: are the gains for women less than for men? , 2003, The Journal of thoracic and cardiovascular surgery.

[20]  V. Dzau.  Predicting the future of human gene therapy for cardiovascular diseases: what will the management of coronary artery disease be like in 2005 and 2010? , 2003, The American journal of cardiology.

[21]  R. M. Satava,et al.  Disruptive visions: Biosurgery , 2003, Surgical Endoscopy And Other Interventional Techniques.

[22]  Laura P Coombs,et al.  Use of continuous quality improvement to increase use of process measures in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial. , 2003, JAMA.

[23]  J. Smith,et al.  The influence of gender in patients undergoing coronary artery bypass graft surgery: an eight-year prospective hospitalized cohort study. , 2003, Journal of the American College of Surgeons.

[24]  M. Mann,et al.  Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. , 2001, The Journal of thoracic and cardiovascular surgery.

[25]  J. Polak,et al.  Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial , 1999, The Lancet.

[26]  M. Mann,et al.  Cell cycle progression: new therapeutic target for vascular proliferative disease. , 1998, Circulation.

[27]  E J Topol,et al.  Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. , 1998, Circulation.

[28]  E L Hannan,et al.  Identification of preoperative variables needed for risk adjustment of short-term mortality after coronary artery bypass graft surgery. The Working Group Panel on the Cooperative CABG Database Project. , 1996, Journal of the American College of Cardiology.

[29]  G. E. Green,et al.  Coronary bypass surgery with internal-thoracic-artery grafts--effects on survival over a 15-year period. , 1996, The New England journal of medicine.

[30]  T. Chalmers,et al.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration , 1994, The Lancet.

[31]  B. Gersh,et al.  Effect of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the coronary artery surgery study (CASS): 10-Year follow-up , 1992 .

[32]  L. T. Sheffield,et al.  Ten-year follow-up of quality of life in patients randomized to receive medical therapy or coronary artery bypass graft surgery. The Coronary Artery Surgery Study (CASS) , 1990, Circulation.

[33]  B. Brent,et al.  Coronary artery bypass surgery in patients with left ventricular dysfunction. , 1986, The American journal of medicine.

[34]  Cass Principal Investigators and Their Associates.  Myocardial infarction and mortality in the coronary artery surgery study (CASS) randomized trial. , 1984, The New England journal of medicine.

[35]  L. Wilkins.  Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Quality of life in patients randomly assigned to treatment groups. , 1983, Circulation.

[36]  C. Maynard,et al.  Results of coronary artery surgery in patients with poor left ventricular function (CASS). , 1983, Circulation.

[37]  G. Johnson,et al.  The internal mammary artery graft. Its longevity after coronary bypass. , 1981, JAMA.

[38]  T. Takaro,et al.  Treatment of chronic stable angina. A preliminary report of survival data of the randomized Veterans Administration cooperative study. , 1977, The New England journal of medicine.

[39]  R. Califf,et al.  Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. , 2005, JAMA.

[40]  B. Gersh,et al.  Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up. CASS Investigators. , 1992, Journal of the American College of Cardiology.

[41]  Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. , 1984, The New England journal of medicine.